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1 Zusammenfassung 
Die autosomal dominante polyzystische Nierenerkrankung (ADPKD) ist eine genetische 
Erkrankung, welche charakterisiert ist durch die Zerstörung der Nierenarchitektur und den 
Verlust der renalen Funktion auf Grund progressiver bilateraler Ausbildung zahlreicher 
Zysten. Es konnte gezeigt werden, dass die Ausbildung solcher Zysten bereits sehr früh im 
Uterus der Mutter beginnt, so dass zwischen dem 18. und 40. Lebensjahr 50% des normalen 
Nierenparenchyms durch Zysten ersetzt sind. Bei den meisten ADPKD Patienten wird die 
glomeruläre Filtrationsrate (GFR) der erkrankten Nieren durch kompensatorische 
Hyperfiltration bis ca. zur 4. Lebensdekade aufrechterhalten. Die Hyperfiltration basiert auf 
der Gegenreaktion verbleibender funktionstüchtiger Nephrone, den fortschreitenden 
Funktionsverlust des Nierengewebes auszugleichen. Die polyzystische Nierenerkrankung 
kann früh in ihrem Verlauf diagnostiziert werden, und stellt ein ideales Modell dar, um den 
Mineralstoffhaushalt in frühen Stadien einer chronischen Nierenerkrankung („chronic kidney 
disease“, CKD) zu studieren. In der vorliegenden Arbeit wurde die ADPKD als 
Modellkrankheit für CKD Stadium 1 (GFR > 90 ml/min/1.72 m
2
) und 2 (GFR 60-90 
ml/min/1.72 m
2
) gewählt, um den Kalzium-Phosphat–Haushalt und die Wirkung von 4 
hormonalen Faktoren (Fibroblast Growth Factor 23 [FGF23], Vitamin D, Parathormon [PTH] 
und Klotho) zu ergründen. 
FGF23 ist ein phosphaturisches Hormone welches von den Osteozyten ausgeschüttet wird. 
Erhöhte Mengen dieses 30 kDa schweren Peptids wurden sowohl im Serum von Patienten mit 
Tumor-induzierter Osteomalazie (TIO) gefunden, als auch bei Patienten mit anderen 
genetischen Erkrankungen wie der autosomal dominanten hypophosphatämischen Rachitis 
(ADHR) basierend auf einer Mutation des Gens welches für FGF23 kodiert, der autosomal 
rezessiven hypophosphatämischen Rachitis (ARHR) basierend auf einer 
Inaktivierungsmutation des Dentin Matrix Acidic Phosphoprotein (DMP1), und bei X-linked 
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Hypophosphatemia (XLH) basierend auf einer Inaktivierungsmutation von PHEX, welches 
dazu beiträgt, dass FGF23 vor Degradierung abgeschirmt wird. Bei all diesen Erkrankungen 
ist die Serumkonzentration von FGF23 erhöht und führt zu massiver renaler 
Phosphatausscheidung. Bei Patienten mit chronischer Nierenerkrankung im Stadium 1 und 2 
trägt die beginnende Erhöhung von FGF23 im Serum dazu bei, den Phosphatgehalt im Blut 
im Normbereich  zu halten. Unsere Resultate bei Patienten mit ADPKD mit CKD 1 und 2 
zeigten interessanterweise bezüglich FGF23 ein anderes Bild als bei Patienten mit anderen 
Nierenerkrankungen. ADPKD Patienten zeigten im Vergleich mit anderen CKD Patienten 
massiv erhöhte FGF23 Werte im Serum. Ähnlich wie bei Patienten mit TIO, ADHR, ARHR 
oder XLH, waren die Konzentrationen von FGF23 auch bei normaler GFR erhöht. Ein grosser 
Unterschied zu den genannten Erkrankung war jedoch, dass trotz ähnlichen FGF23 
Serumspiegeln keine Hypophosphatämie bei den ADPKD Patienten vorlag, was auf eine 
Resistenz auf FGF23 schliessen lässt. 
Klotho ist der hauptsächlichste Rezeptor von FGF23. Dieses 130 kDa schwere Protein hat 
eine einzelne transmembrane Domäne und ist hauptsächlich in der Niere, der 
Nebenschilddrüsen und der Choroidea im Auge exprimiert. Sobald Klotho vom Endosom zur 
Zellmembran transloziert, wird die extrazelluläre Domäne von Klotho (solubles α-Klotho) 
abgetrennt und in den Blutkreislauf freigesetzt. FGF23 benötigt die c-terminale Bindung zu 
Klotho um den kanonischen Rezeptor FGFR1c zu aktivieren. Diese Aktivierung wiederum 
führt in proximalen Tubuluszellen der Niere zur verminderten Membranexpression der 
NaPiIIa und NaPiIIc Phosphatkotransporter, wie auch zur Verringerung der 1α-hydroxylase 
Expression und Aktivität. Da bei Patienten mit ADPKD die FGF23 Serumkonzentrationen 
massiv erhöht sind, analysierten wir die Serumspiegel von solublem -Klotho bei ADPKD 
Patienten und verglichen sie mit Patienten derselben CKD Stadienmit anderen 
Grundkrankheiten. Diese Analyse zeigte, dass bei ADPKD Patienten die Konzentration von 
zirkulierendem -Klotho stark vermindert ist. Basierend auf diesem Resultat vermuten wir, 
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dass die periphere Resistenz auf FGF23 mit der tiefen Expression von zirkulierendem -
Klotho begründet werden kann.  
Zusammenfassend lässt sich festhalten, dass die spezifische Erhöhung von FGF23 in frühen 
CKD Stadien und die assoziierten niedrigen Klotho Werte eine spezifische Manifestation der 
polyzystischen Nierenerkrankung darzustellen.  Diese Veränderungen könnten auch mit der 
Zystenbildung verknüpft sein. Alternativ könnte die Entwicklung der Zysten und die 
darauffolgende Zerstörung des Nierenparenchymszur niedrigen Expression von Klotho 
beitragen. Viele Zysten bilden sich im distalen Tubulussegment, welches auch die 
Hauptlokalisation der Transmembranexpression von Klotho ist. Die pathophysiologische 
Bedeutung der veränderten FGF23 und Klotho Expression und deren Auswirkungen auf den 
Mineralhaushalt bei Patienten mit ADPKD muss in weiteren Studien geklärt werden. 
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2 Summary 
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized 
by the destruction of the kidney architecture and loss of renal function due to progressive 
bilateral growth of numerous cysts.
1, 2
 It has been demonstrated that the development of cysts 
is a process that starts already early in uterine, thus by the age between 18 and 40 years the 
cysts replace approximately 50% of the normal parenchyma.
3
  
In most ADPKD patients, glomerular filtration rate (GFR) of the affected kidney remains 
preserved up to the 4
th
 decade due to a compensatory glomerular hyperfiltration in the 
remaining nephrons counteracting the ongoing loss of functional renal tissue.
4, 5
 ADPKD can 
easily be detected early in the course of the disease and represents an ideal condition to study 
mineral metabolism at an early stage of chronic kidney disease (CKD) since GFR remains 
stable for a long time and the course of the disease is generally not confounded by therapies. 
Using ADPKD as an optimal model to study early onsets of CKD stage 1 (GFR > 90 
ml/min/1.72 m
2
) and stage 2 (GFR 60-90 ml/min/1.72 m
2
), we mainly focused on the 
phosphate / calcium homeostasis and involvement of the 4 major hormonal players 
influencing the mineral metabolism of CKD (Fibroblast Growth Factor 23 [FGF23], Vitamin 
D, Parathormon [PTH] and Klotho). 
Firstly, FGF23 is a known as a phosphaturic hormone that is secreted by osteocytes.
6, 7
 
Serum levels of this 30 kD peptide were found to be elevated in tumor induced osteomalacia 
(TIO)
8, 9
 as well as in several genetic diseases such as autosomal dominant hypophosphatemic 
rickets (ADHR) secondary to a mutation of the gene which encodes for FGF23,
10, 11
 
autosomal recessive hypophosphatemic rickets (ARHR) secondary to an inactivating mutation 
of Dentin Matrix Acidic Phosphoprotein (DMP1),
12, 13
 and X-linked hypophosphatemia 
(XLH) secondary to inactivating mutations of PHEX,
14
 which makes FGF23 less accessible to 
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degradation. In disease states where FGF elevation has been described, its accumulation led to 
severe renal phosphate wasting. In contrast, elevated FGF23 levels in CKD patients may play 
an essential role in maintaining normal serum phosphate levels at CKD stages 1 and 2.
15-17
 
Our first finding, using ADPKD as a model for early CKD, was different to other diseases 
inducing kidney insufficiency. ADPKD presented with significantly higher expression levels 
of FGF23, when compared to CKD patients not affected with polycystic kidney disease .
18
 
Similar to TIO, ADHR, ARHR and XLH, this finding in ADPKD patients occurred even in 
the presence of a normal GFR. However, the marked hypophosphatemia, typical for tubular 
disorders is not present in ADPKD, suggesting a resistance to FGF23 in this disease. 
Klotho has been determined to be the main co – factor for FGF23. The gene Klotho 
encodes for a 130 kD protein with a single transmembrane domain that is mainly expressed in 
the kidney, the parathyroid glands and the choroid plexus.
19
 Once Klotho protein is 
translocated from the endosome to the cell membrane, the extracellular domain of Klotho 
(soluble α-Klotho) may be cleaved and released into the blood stream.20 FGF23 needs to bind 
Klotho protein by its c-terminal part to activate the canonical receptor FGFR1c which leads to 
reduced membrane expression of the NaPiIIa and NaPiIIc co-transporters as well as down 
regulation of 1-alpha hydroxylase.
21
 Subsequently to the finding that FGF23 is markedly 
elevated in ADPKD, we analyzed other CKD patients not affected with polycystic kidney 
disease yet in similar CKD stages, and established that our ADPKD patients present 
significantly lower levels of Klotho when compared to non polycystic CKD patients. 
Therefore we concluded that this results pointed toward the hypothesis that peripheral 
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resistance to FGF23 could be triggered by lower local expression or circulating levels of 
Klotho.  
In summary we established that the specific elevation of FGF23 in early stages and the 
associated decrease of Klotho is a manifestation specific for polycystic Kidney disease and 
might be implicated in the development of cysts. Whereas alternatively cyst development and 
the subsequent destruction of the epithelial parenchyma may contribute to the low levels of 
Klotho expression, especially since the origin of cyst development is considered to be the 
distal convoluted tubule, the location of the Klotho transmembrane molecule expression.  
Yet, the pathophysiological importance of level alterations of FGF23 and Klotho and the 
associated implication on the mineral homeostasis of ADPKD patients is subject to further 
research efforts. 
22
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4 Autosomal Dominant Polycystic Kidney Disease 
4.1.1 Genetic Mutations and Phenotype 
Autosomal dominant polycystic kidney disease (ADPKD) is a common, monogenic multi-
systemic disorder characterized by the development of renal cysts leading to a subsequent 
complete destruction of the renal parenchyma in the fifth or sixth decade of a human life.
23, 24
 
Its autosomal dominant characteristics manifest due to the fact that in case one parent carries 
the disease, there is a 50% chance that the disease will be passed on to the child, therefore will 
be inherited dominantly throughout the generations. 
It has a prevalence of 1: 400 to 1: 1000 in white populations and is accounted for 10 – 15% of 
the end stage renal disease cases leading to mandatory maintenance on dialysis.
25
 In 85% of 
the ADPKD cases the underlying genetic mutation is located on the chromosome 16 linked on 
a α-globulin complex, defined as the polycystic kidney disease 1 gene (PKD 1) that encodes 
for the protein polycystin 1 (PC1)
26
. The gene product is a membrane bound protein with a 
large extracellular structure containing a C type lectin domain, leucin rich and 
immunoglobulin like repeats and type III fibronectin domains.
27
 This structure suggest that 
PC1 can mediate cell – cell and cell-matrix interaction.27 The majority of the remaining cases 
are associated with a defect on chromosome 4 defined as polycystic kidney disease 2 gene 
(PKD2), encoding for polycystin 2 (PC2)
28
, which is as well a membrane bound protein that 
shows an integral component of an ion channel complex.
29
 The cases that are determined to 
be caused solely due to a mutation in PKD2 are found to be less severe than the phenotypes 
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based on the PKD1 mutations.
28, 30
 Earlier on it has been postulated that PC1 is a regulator of 
PC2, and that both proteins are involved in a signaling pathway that is essential for normal 
cytogenesis and renal tubulogenesis. This phenotypic variability is based on the PKD genic 
and allelic variability and ability to act as modifier genes, where the proteins encoded by these 
genes are involved in mechanosensory ion channel complexes and integrity of the 
extracellular matrix.
24, 31
 Cyst development therefore is caused by somatic mutations in the 
PKD genes leading to loss heterozygosity (LOH).
32
 In fact, one hypothesis persisting today, 
states that the mutation found in the germline is not in itself sufficient to produce a cyst, and a 
second sporadic event, genetic or otherwise, is also required (two hit model).
33
 It is actually 
accepted that the second hit necessary for cysts formation inactivates the wildtype copy of the 
allele, which is inherited from the healthy parent
34
. Although the exact mechanism of cyst 
development still builds on postulations that remain to be confirmed,  it has been agreed upon 
that most of the cysts arise first in the nephron from the loops of Henle, distal tubules and 
collecting ducts.
35, 36
 
 
4.1.2 Cyst formation, Phenotypes and Organ Manifestations 
The pathogenesis of ADPKD has been divided into three phases. The initiation phase where 
normal quiescent epithelial cells become hyperproliferative, the cyst growth phase and the 
cyst expansion phase caused by a proliferation of cyst epithelial cells and increased fluid 
secretion, as well as extracellular metric synthesis.
37
 Additional signaling pathways that under 
normal circumstances regulate cyto- and tubulogenesis during the phase of cell proliferation 
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are shown to be highly dysfunctional in ADPKD causing the typical formation of cysts.
26
 At a 
certain point in the cyst growth phase the cyst detaches from the original nephron and 
continues to grow isolated and autonomous.
38
 
ADPKD patients form renal cysts as described focally from the nephron, current research 
focus on the hypothesis that the beginning of the cyst formation is a process that starts in the 
loop of Henle and the distal convoluted tubules.
36
 An additional manifestation of the ADPKD 
disease state is the cyst development in the intrahepatic biliary tree, where epithelial cells 
from these independent cysts are monoclonally derived.
39
 Development of hepatic cysts is a 
common manifestation along the disease progression of ADPKD and happens generally after 
the development of renal cysts, hence later in the disease state. Liver cysts are responsible for 
most hepatic complications, where as in the later stage of ADPKD liver changes may 
occasionally be encountered, including congenital hepatic fibrosis and segmental dilation of 
the biliary tract.
39
 The prevalence and number of hepatic cysts in patients with ADPKD 
increase with progression of age, female gender, severity of renal cystic disease, and severity 
of decline of renal function. 
40
 By age 60, nearly 80% of patients have hepatic cysts. 
Additional manifestations of ADPKD are cerebral aneurysms, pancreatic cysts, cardiac valve 
disease, colonic diverticula, abdominal wall, hypertension and inguinal hernia. Malformations 
of selected vasculature, including intracranial aneurysms and aortic root dilatation may be due 
to altered expression and function of the PKD gene in arterial smooth muscle cells and 
myofibroblasts
41
.  
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Historically one of the main indications if an individual is at risk to develop cystic kidney 
disease was based on family history, since the mutation is inherited dominantly and has a 50% 
chance to be carried on if one parental carrier exists. New mutations account for only 3.6% of 
cases, where family history is not always positive
23
. Current diagnostic methods involve 
magnetic resonance imaging (MRI) and Ultrasound evaluation including the proper analysis 
of family history
42
 and screening for mutations in the PKD gene via genetic testing, yet the 
latter option is considered limited due to methodological restrictions. Therefore it is of 
essence to individualize the patient care and screening in order to get a complete picture of the 
status quo and a possible forecast on ADPKD development. 
4.1.3 ADPKD – preserved CKD 1 stage due to hyperfiltration 
ADPKD is a disease that has its onsets already in uterus and progresses slowly with the 
development form early childhood to adulthood and further.
43
 Due to its slow progression and 
the diagnostic imaging tools and the proper screening regarding family history, a final 
diagnosis of APDKD can be provided already in early adulthood.
42
 The affected patients 
present with preserved kidney function due to compensatory hyperfiltration, that can be 
defined as chronic kidney disease (CKD) stages 1 and 2.
41
 In the case of ADPKD, 
hyperfiltration is a state where the remaining functionally not affected nephrons go into 
overcompensation to maintain the required glomerular filtration rate of the kidney.
41
 
Diagnostic markers for ADPKD can be decreased effective renal plasma flow (ERPF), 
increased filtration fraction (FF) and urinary albumin excretion (UAE) and finally enlarged 
total renal volume (TRV). These parameters may be better or more so additional markers for 
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disease severity in combination with the overall glomerular filtration rate (GFR).
44
 As stated 
earlier; despite this significant organ dysfunction, the preserved and maintained filtration for a 
prolonged period of time, makes ADPKD an appropriate model to study mineral ion 
homeostasis in early renal disease, defined as CKD stage 1 and 2 (eGFR > 60ml/min). 
44
 
 
5 Mineral Ion Metabolism in Chronic Kidney Disease 
5.1 Calcium & Phosphate Homeostasis 
5.1.1 Regulations and Transport of Phosphate 
The disruption and dysregulation of phosphate homeostasis happens early in the course of 
chronic kidney disease. Accompanied by a decrease in calcitriol production and elevation of 
parathyroid hormone (PTH) levels, the derangements of mineral ion homeostasis and 
hormone regulation characterize the manifestation of secondary hyperparathyroidism (sHPT), 
while defining the disease state of chronic kidney failure.
45
 
In a healthy person, serum phosphate concentration is maintained within a narrow range (0.8 
– 1.5mmol/L), despite variable amounts of phosphate that is daily ingested. 30% of the total 
phosphate ingested by nutrients is excreted through the gastrointestinal tract and 70%, which 
accounts for approximately 700 mg/day, is excreted by the kidneys. In relation to a normal 
GFR, 15% of the filtered load of phosphate must be excreted; the tubular reabsorption of 
phosphate is equal to about 85% of the filtered load. The absolute value for tubular 
reabsorption of phosphate will vary depending upon the amount of phosphate requiring 
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excretion. The mechanisms controlling phosphate homeostasis are greatly depending on 
various effectors that influence and regulate phosphate homeostasis.
46
 The molecular 
mechanism regarding phosphate excretion and reabsorption in the proximal tubule is 
mediated by Na-dependent, secondary-active transport mechanisms (Na/Pi II transporters). 
The influx of phosphate from the tubular lumen into the epithelial cell involves brush border 
membrane-associated Na/Pi co-transporters which are rate-limiting and targets for 
physiologic/pathophysiologic regulation. 
47-49
 Three types of Na/Pi co-transporters have been 
identified. Characterization of the three different types varies among the localizations along 
the proximal tubule. The type I Na/Pi co-transporter is localized in the brush border 
membrane of proximal tubular cells.
50, 51
 It still remains to be clarified if this transporter is 
essential to facilitate phosphate uptake. Current opinion is that type I mediated Na/Pi 
cotransport does not have the characteristics and regulatory features of brush border 
membrane Na/Pi cotransport and suggested a channel function, mediating the flux of chloride 
and organic anionic compounds. Two closely related type II Na/Pi co-transporters are 
expressed in the apical membrane of absorptive/reabsorptive epithelia, the type IIa
52
, type 
IIb
53
, and type IIc
52
. Type IIa and type IIc are majorly expressed in kidneys, but neither of 
them could be detected in the intestine. Type IIb is expressed in small intestine and type II 
alveolar cells, but not in kidney.
54, 55
  
This finding makes the Na/Pi co-transporter Type IIa and c the essential phosphate transporter 
mechanism in the renal cells along the proximal tubules.
55-57
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Yet there is another phosphate transport system worth mentioning, Pit1 and Pit2 were 
identified as the mammalian representatives of type III sodium-phosphate symporters (NaPi-
III), these NaPi-III transporters do not share homology or similarity with the above described 
phosphate co – transporters. At least Pit2 contributes also to renal phosphate reabsorption, is 
localized in the proximal tubular brush border membrane, and regulated by phosphate and 
PTH (Ravera..Murer..Sorribas et al 2008 oder 2009, Picard, Capuano…Wagner 2010). 
 
5.1.2 Regulation and Transport of Calcium 
Similar to phosphate, it has been determined that calcium shows level imbalance as soon as 
renal failure occurs. A homeostatic system works to ensure that the concentration of 
extracellular calcium is tightly controlled. Under normal conditions (1.1 – 1.4 mmol/L), 
serum ionized calcium fluctuates by a maximum of ± 2%.
58
 An increased concentration of 
free calcium not bound to protein in serum, defined as ionized calcium (Ca
2+
) is used as a key 
signaling messenger in the initialization of a wide range of cellular events. Ca
2+
 signals 
control many cellular functions ranging from short-term responses such as muscle contraction 
and hormonal secretion, such as secretion of parathyroid hormone, to long-term regulation of 
cell growth and proliferation.
59
 It has been shown that Ca
2+
 signaling can induce apoptosis or 
less specific necrosis under special conditions.
60
  
Calcium enters the cells by any of the general classes of channels, including voltage operated 
channels, second messenger-operated channels, store-operated channels and receptor-operated 
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channels. In non-excitable cells, not participating in the triggering of an action potential, the 
major Ca
2+
 entry pathway are store-operated channels, in which the emptying of intracellular 
Ca
2+
 stores activates Ca
2+
 influx. The increase in Ca
2+
 levels has been associated with cellular 
dysfunctions in a variety of conditions such as diabetes mellitus, hypertension, 
hyperparathyroidism and chronic renal failure.
61, 62
 Furthermore, dysregulation of Ca
2+
 
homeostasis involving the endoplasmic reticulum and store-operated calcium channels has 
been manifested in neurodegenerative disorders such as Alzheimer’s patients63, in patients 
with immunodeficiency, acute pancreatitis
64
 and polycystic kidney disease.
65
 These processes 
are dependent on the regulatory function of calciotropic hormones and their effector tissues in 
the kidney, intestine, and bone. Essential for this regulation mechanism is the calcium-PTH 
axis. Extracellular calcium levels are the primary marker of PTH secretion and production 
and, hence, PTH is a key regulator of serum calcium levels.
66
  
 
5.2 Hormonal Control of Phosphate and Calcium Homeostasis 
5.2.1 PTH and Vitamin D 
The principal function of PTH is to keep blood Ca
2+
 constant by releasing calcium from bone, 
reducing renal excretion of calcium, increasing urinary excretion of phosphorus, and stimulate 
the production of the active form of vitamin D (calcitriol) in the kidneys. Vitamin D and the 
vitamin D receptors (VDRs) are expressed within the nucleus of parathyroid cells and play 
important roles in calcium homeostasis. The kidneys are able to respond to PTH by 
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reabsorbing calcium, excreting phosphorus, and increasing production of calcitriol, making 
PTH one of the regulatory factors for renal physiology.
67, 68
 In the progression of CKD, 
increased PTH levels are one of the manifestations of secondary hyperparathyroidism (sHPT), 
causing increased proliferation of parathyroid gland tissue to cover the demand for 
sequestering PTH. This increased demand is on one hand due to high Pi and low Ca
2+
 based 
on the calcium phosphate product (CaxP) insolubility, on the other hand due to skeletal 
resistance to the action of PTH; which is postulated to be caused by down regulation of PTH 
receptors in bone cells, increased levels of osteoprotegerin and possible decreased levels of 
bone morphogenetic proteins.
69
 In human physiology PTH levels are required to mobilize 
bone calcium in order to maintain normal bone turnover and calcium homeostasis. This so 
called bone turnover or bone remodeling is done by bone remodeling units of osteoblasts and 
osteoclasts, coupled together via a paracrine cell signaling. The process of bone resorption by 
the osteoclasts releases stored calcium into the systemic circulation therefore regulates 
calcium balance, making PTH a key factor in bone physiology. 
Furthermore, and due to its regulatory involvement regarding the development of CKD, PTH 
has become along with phosphate and calcium the most important screening factor in daily 
clinical practice, and its maintenance and control has become one of the most challenging 
tasks for a physician.
70
 
Along with PTH, vitamin D plays a pivotal role in the regulation of calcium–phosphate 
homeostasis. Vitamin D deficiency is a significant risk factor for the development of specific 
chronic diseases.
71
 In CKD, vitamin D deficiency, specifically low calcitriol levels, is highly 
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prevalent and associated with sHPT, leading to serious mineral and bone disorders.
72
 Many 
currently applied guidelines have determined for Vitamin D to be supplemented already in 
patients determined to be CKD stage 3 (National Kidney Foundation (K/DOQI) guidelines). 
The treatment of CKD patients with Vitamin D sterols or analogues has been well established 
in daily clinical practice. Both the supplementation of Vitamin D and the control of PTH have 
been well established treatment targets, yet the long term consequences and the involvement 
of and dependence on different hormonal regulators and effectors are still to be determined.  
 
6 Phosphaturic Hormones 
6.1 Fibroblast Growth Factor Family 
The fibroblast growth factor (FGF) family consists of 22 individual members ranging from 
FGF1 – FGF23, all with a variety of functions. Human FGFs contain 150–300 amino acids 
and have a conserved core of 120 amino acids with 30–60% identity to each other.73-75  
The FGF23 gene encodes for an approximately 32-kD (251 amino acids) protein with an N-
terminal region that contains the FGF homology domain and a novel 71–amino acid C-
terminus that was originally discovered by homology-based PCR screening of a mouse 
embryonic cDNA library. The FGF23 gene is located on Chr 12p13 and is, due to its genetic 
and amino acidic identity of 24%, genetically grouped with the FGF19 and 21 genes.
76
 
77
 
Based on their function as growth factors, the FGFs family members are defined to act as 
hormones either classified as intracrine, paracrine and endocrine FGFs according to their 
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mechanisms of action. Intracrine FGFs, FGF11-FGF14, are not secreted extracellulary. They 
act as intracellular molecules in an FGF receptor-independent manner.
78, 79
 They interact with 
intracellular domains of voltage gated sodium channels and with a neuronal MAPK scaffold 
protein. The only known role for intracrine FGFs is the regulation of the electrical excitability 
of neurons and possibly other cell types.
80, 81
  
The remaining FGFs members are determined to act as paracrine hormones and are mostly 
secreted proteins with cleavable N-termini that act as secreted signal peptides. Except for 
FGF1 and FGF2, which have no N-terminal hydrophobic sequences, which is atypical for 
secreted proteins. FGF1 and FGF2 are postulated to be released from damaged cells or by an 
exocytic mechanism that is independent of the endoplasmic reticulum-Golgi pathway.
82
 
The paracrine FGFs, which mediate biological responses as extracellular proteins that are 
known to have a heparin binding site to and activating cell surface tyrosine kinase FGF 
Receptor (FGFR) with heparin/heparan sulphate as a cofactor.
83
 The FGFR genes have been 
categorized as 4 different types FGFR 1 – FGFR4, and detected in both humans and mice. 
These genes encode receptor tyrosine kinases that are approximately 800 amino acids long 
and contain an extracellular ligand-binding domain with three immunoglobulin-like domains 
(I, II and III), a transmembrane domain and a divided intracellular tyrosine kinase domain. 
The immunoglobulin-like domain III is an essential structural site with high ligand-binding 
specificity.
84
 To summarize, previous research has determined 7 major FGFR proteins 
(FGFRs 1b, 1c, 2b, 2c, 3b, 3c and 4) to be generated from four different FGFR genes, via 
alternative and specific splicing, with various ligand-binding specificity. This diversity 
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contributes to the wide spectrum of biological activities induced by these growth factors, and 
has added majorly to their importance to participate in molecular and cellular processes.
85
 
As mentioned before, the paracrine FGFs have a heparin-binding site and interact with their 
corresponding receptors to induce their biological activity. It has been established that 
heparin-like molecules are necessary for the stable interaction with FGFRs and their 
immunoglobulin-like domain III in order to induce proper local signaling.
86
 It has been shown 
that sufficient activation can only be induced when a corresponding co-factor is present, the 
FGF protein alone binds rather insufficiently to the corresponding receptor and binding occur 
only very weakly, with insufficient conformational changes of the receptor, hence insufficient 
signal transduction. It is known that when FGF binding occurs, FGFRs undergo a functional 
dimerization, receptor transphosphorylation and activation of four key downstream signaling 
pathways: RAS-RAF-MAPK, PI3K-AKT, STAT and PLCγ.86, 87 
The FGF proteins known to act paracrine on their neighboring cells are greatly dependent on 
appropriate receptor activation and signal induction. The last groups that need mentioning are 
the endocrine FGFs, FGF15/19, FGF21 and FGF23, which are postulated as well to mediate 
their biological responses in an FGFR-dependent manner.
88
 Different from their paracrine 
siblings, the endocrine FGFs have shown that they bind to their corresponding receptor and 
heparin/heparan sulphate as a co-factor with very low affinity. The observation of their 
reduced heparin-binding affinity was postulated to explain that this specifically enables 
endocrine FGFs to function in an endocrine manner, acting not paracrine on their neighboring 
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cells but having the ability to participate in signaling processes on different tissue and organ 
systems.
89
  
 
6.2 Fibroblast Growth Factor 23 
Fibroblast Growth Factor 23 (FGF23) is a 30-kDa protein, containing 251 amino acids, with 
an N-terminal region containing the FGF homology domain and a novel 71-amino acid C 
terminus. FGF23 can be inactivated when cleaved at the 
176
RXXR
179
 motif, generating 
biologically inactive N- and C-terminal fragments.
90
  
The protein FGF23 acts as a phosphaturic factor and has been identified as a pathogenetic 
molecule to be involved in three different hypophosphatemic diseases and the inappropriate 
regulation of vitamin D metabolism, since it has the ability to strongly suppress the 1α-
hydroxylase activity in the kidney. Its features make it functionally distinct from other 
members of this family.
91
 
Firstly, FGF23 was identified to act as a phosphatonin in patients with autosomal dominant 
hypophosphatemic rickets (ADHR), where its mutations stabilize the FGF23 protein. The 
mutations occur at the 
176
RXXR
179
 site (R176Q, R179W, and R179Q) where they prevent 
cleavage and inactivation of FGF23 leading to increased circulating levels.
92
 Another disease 
state with inappropriately high levels of FGF23 is X-linked hypophosphataemia (XLH), a 
disease caused by inactivating mutations of the PHEX gene, the loss of a membrane-bound 
protease resulting in increased circulating levels of FGF23.
93, 94
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Finally, in tumor-induced osteomalacia (TIO), also called oncogenic osteomalacia, tumors 
secrete large amounts of FGF23. This disease is an acquired hypophosphatemic disorder with 
phenotypic similarity to ADHR and XLH. Based on the phenotypic similarity between the 
three diseases, an unproven model has been postulated. When presumed that PHEX is 
involved in degrading active full length FGF23 into inactive fragments and increased levels of 
FGF23 are causing the phosphate wasting in ADHR, XLH and TIO, previous research has 
shown that in ADHR and XLH a mutation in the FGF23 genes occurs that renders it resistant 
to PHEX dependent cleavage, in TIO the increased production of FGF23 by the tumor 
overwhelms the capacity of PHEX to influence the inactivation of FGF23 proteins.
94
 Leaving 
all three diseases stated with the phenotypic outcome of inappropriate inorganic phosphate 
wasting.
95
 
Based on this finding, recent studies have determined FGF23 to be a phosphaturic hormone 
that is able when not effectively degraded by the PHEX dependent pathway, to inhibit 
sodium-dependent phosphate uptake in the renal proximal tubule, causing massive phosphate 
wasting and additionally inhibiting the activation of Vitamin D by the active suppression of 
1α-hydroxylase.  
Early on FGF23 has been identified to be secreted by osteocytes.
96
 Yet its physiological role 
as an endocrine hormone primarily targets the kidney and parathyroid glands. This biological 
action plan has led to the definition of the so called kidney-bone axis regulated by FGF23, 
where it also regulates the bone mineralization via its ability to induce renal phosphate 
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wasting down, down regulating the Na/Pi co-transporters and causing suppression of renal 
and intestinal phosphate reabsorption.
97
 FGF23 induced hyperphosphaturia has been 
associated with significant decrease of bone mass and osteomalacia. In summary, FGF23 
impact on the kidney derives from the fact that it has a highly regulating role in the control of 
renal phosphate homeostasis. 
As mentioned in the beginning, FGF23 has been associated with an inhibition of 1α-
hydroxylase , which is expressed in the proximal convoluted tubule, distal convoluted tubule, 
the cortical and medullary part of the collecting ducts 
98
 and mediates the conversion of native 
vitamin D to calcitriol. The study from Shimana et al.
96
 provided proof that FGF23 yet 
regulates renal expression of Na/Pi2a co-transporter in a Vitamin D Receptor (VDR) 
independent manner and that calcium is a potent stimulator of FGF23 production via VDR-
independent pathway and that via the suppression of the 1α-hydroxylase FGF23 directly 
impacts the conversion of Vitamin D to calcitriol.
91, 99
 FGF23 has his position as a regulator 
that acts upon feedback to maintain physiological phosphate balance, excess of FGF23 
induces hypophosphatemia which mediates the suppression of PTH, on the other hand 
induces FGF23-mediated low calcitriol levels the stimulation of PTH. FGF23 also acts 
directly on the parathyroid tissue to inhibit PTH synthesis and secretion. The complexity of 
the FGF23 mediated regulation of PTH and the feedback loop via the suppression of Vitamin 
D has been illustrated by Komaba et al, as presented below.100 
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Figure 1: FGF23–parathyroid interaction: implications in chronic kidney disease100 
 
6.3 The FGF23 involvement in chronic kidney disease 
Since FGF23 has been established as an important hormonal factor to impact on renal 
physiology, studies have been conducted to clarify its role on CKD. Fliser et al
101
. have 
determined in the MMKD study that elevated circulating FGF23 levels are also found in 
patients with advanced CKD. In this setting the elevation of serum FGF23 levels is thought to 
counteract the retention of phosphate and is known to be accompanied by a rise in PTH and a 
fall in calcitriol levels.
17, 102
  
Along the line of FGF23 counteracting the retention of phosphate to maintain balance and act 
as a regulator in CKD, Guiterrez et al. 
103
 have associated increased levels of FGF23 with 
increased mortality amongst patients on hemodialysis. They determined that FGF23 was an 
earlier marker for risk of death even before first hyperphosphatemia develops. This study 
triggered the question of the temporal sequence of events and changes of the involved 
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parameters and led to further findings that FGF23 in fact precedes the rise of PTH and the 
drop of calcitriol, positioning it as a primary control marker for CKD progression.
17, 102
 
Although this has been postulated for some time, only most recent studies could provide proof 
of the early rise of FGF23 as a potential regulator, leaving the question what is the initial 
trigger to activate the osteocytes to enhance FGF23 secretion?  
 
6.4 Klotho – Autonomous Autocrine Hormone and Co Factor to FGF23 
The Klotho gene encodes a 130-kDa single-pass transmembrane protein with a short 
cytoplasmic domain, consisting of 10 amino acids.
19
 Studies have determined that the short 
cytoplasmic tail is cleaved by ADAM 10 and 17, once it is translocated from the endosome to 
the cell membrane, the extracellular domain of Klotho (soluble α-Klotho) is cleaved and 
released into the blood stream, acting as a paracrine hormone inducing renal signalling.
20
 
Secreted Klotho inhibits the Na/Pi co-transporter 
104
 and activates ion channels TRPV5, 
TRPV6, causing increased cell-surface abundance of the renal epithelial Ca
2+
 channel TRPV5 
by modifying its N-linked glycans.
105
  
Klotho is expressed predominantly in the kidney, but has been detected as well in the 
parathyroid glands and the choroid plexus, the function in these tissues is yet to be completely 
clarified.
19
 Imura at al. recently reported that Klotho interacts with the Na/K/ATPase in all of 
the determined tissues of its expression. Specifically in the choroid plexus it binds to the 
intracellular domain of the Na/K/ATPase, forming a binding structure that travels to the cell 
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surface with Klotho. Yet the molecular mechanism for this specific process still lacks exact 
explanation. 
Mice carrying a loss-of-function mutation in the Klotho gene develop a syndrome resembling 
human aging, including shortened life span, skin atrophy, muscle atrophy, osteoporosis, 
arteriosclerosis, and pulmonary emphysema. On the other hand, overexpression of the Klotho 
gene extends the life span and increases resistance to oxidative stress in mice. These 
observations suggest that the Klotho gene functions as an aging suppressor gene. The shedded 
domain of Klotho (soluble α-Klotho) is hypothesized to suppress the intercellular signaling of 
insulin/IGF1 pathway, which partly contributes to its anti-aging properties.
19, 106, 107
  
 
The phenotypic resemblance of Klotho and FGF23 KO mice has led to the assumption that 
they might influence each other and subsequent to this findings it has been stated that the 
soluble α-Klotho has the ability to bind canonically to the FGFR 1(IIIc) converting it into a 
specific receptor for FGF23. This FGF23 receptor shows a strong affinity that is sufficient for 
interacting with physiological concentrations of FGF23, leading to the hypothesis that the 
biological activity of FGF23 is regulated by the local distribution of Klotho. The discovery of 
Klotho as a receptor modulator has added a potential explanation for Klotho as a potential 
early biomarker in CKD.
108
 
One possibility is that Klotho, in addition to being the co receptor for FGF23, has other 
downstream roles. It needs to be emphasized that the primary site of FGF23 action in the 
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kidney is postulated to be the proximal renal tubule, yet the primary expression site of Klotho 
in the kidney is the distal convoluted tubule. The ability of the shedded α-Klotho to act as a 
proteohormon in a paracrine way contributed to the hypothesis that its influence on phosphate 
reabsorption and Vitamin D activation is indeed in the proximal tubule.
104
  
Additionally to Klothos function as a co-factor to FGF23, it has been associated with the 
physiological regulation of calcium. This finding was based on Klotho mutant mice that 
presented significantly elevated levels of calcium, phosphate and active Vitamin D (1.25-
OH). The mutant animals developed prematurely and became significantly calcified mainly in 
the kidney. The setting suggested that the calcification was due to the elevated metabolites 
that provoke extensive tissue damage that contributed finally to the phenotype of progressive 
aging. Specifically the excess of active Vitamin D has been associated with advanced and 
progressive aging, nominating it as a direct factor. Tsujikawa et al.
109
 demonstrated that life 
span of the Klotho mutant mice can be prolonged when the animals are put on a Vitamin D 
deficient diet. In the physiological process of regulating calcium in organisms, PTH has been 
established as essential factor in renal patients regarding the control of their mineral ion 
metabolism. One of the main functions of PTH regarding the kidney is the maintenance of 
calcium balance in serum, protecting the organism from hypocalcaemia. In relation to Klotho 
and its contribution to calcium regulation, PTH has soon been tied to Klotho, identifying 
Klotho as a potential early regulator of PTH secretion. PTH secretion is known to be 
regulated by a G-coupled protein calcium sensing receptor,
110
 the interaction of the 
Na/K/ATPase Klotho complex has been added to the list of regulators, based on the finding 
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that in Klotho knockout mice PTH secretion seems to be completely blunted. It remains to be 
clarified if the action of Klotho on the Na/K/ATPase has a central role or is a secondary effect 
on PTH via its regulation of the active Vitamin D metabolite.
111
 
 
7 Purpose 
The regulatory role of phosphaturic hormones has been intensely studies since the beginning 
of the 21
st
 century. The research efforts in the topic of FGF23 and Klotho as regulatory 
factors and early biomarkers have contributed immensely to picture of sHPT development and 
consequences of chronic renal failure. Yet, in order to establish these molecules as valid for 
daily clinical practices, such as early screening markers or potential hormonal therapeutics, 
the picture yet needs to be completed. 
 
The purpose of this dissertation was the analysis of the mineral ion homeostasis in setting of 
early chronic kidney failure, specifically the temporal course of change regarding the 4 
parameters: Vitamin D, PTH, FGF23 and Klotho. As a model for early CKD we initially used 
autosomal polycystic kidney disease, where we included only patients with preserved kidney 
function. We examined phosphate homeostasis in the early onset of polycystic kidney disease, 
studying the different parameters known to be influencing and contributing to development of 
secondary hyperparathyroidism. Our focus was the expression of FGF23 and Klotho in such 
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an early onset of the disease, where we searchedfor possible explanations in regards to the 
clinical setting concerning the ADPKD patients. 
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Abstract 
Background/Objectives: Peripheral resistance to the actions of FGF23 is known to occur in 
renal insufficiency, due to down-regulation of expression of Klotho at the level of the 
parathyroid gland and the kidney. To test whether serum levels of soluble alpha-Klotho reflect 
this phenomenon, the newly available ELISA for Klotho was applied to measure serum levels 
in patients with chronic kidney disease (CKD) stages 1 to 5. 
 
 Design/Setting/Participants/Measurements: Klotho, fibroblast growth factor 23 (FGF23), 
parathyroid hormone (PTH), 1,25-dihydroxy vitamin D3 (1,25D) and other parameters of 
mineral metabolism were measured in serum of 87 patients with various nephropathies. 
Locally weighted scatter plot smoothing function of these parameters were plotted vs. 
estimated glomerular filtration rate (eGFR) to illustrate the sequence of events, and 
appropriate regression models were fitted to estimate the respective changes per each 1ml/min 
eGFR.  
 
Results: With progressing CKD, Klotho linearly decreased whereas both FGF23 and PTH 
showed a plateau at early CKD stages and then a curvilinear increase. The adjusted mean 
Klotho change was -5.7 pg/ml (95%CI -4.1 to -7.5 pg/ml, P<0.0001) for each -1 ml/min 
eGFR change. FGF23 departed from the plateau at an eGFR of 48.6 ml/min (95%CI 41.0 to 
56.1 ml/min) whereas PTH departed at an eGFR of 35.3 ml/min (95%CI 21.7 to 50.0 ml/min).  
 
Conclusion: The sequence “low Klotho first - high FGF23 second” observed in CKD 
suggests a cause-and-effect relationship; serum level of soluble alpha-Klotho might be 
currently the most sensitive biomarker of renal damage and of CKD progression. 
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Introduction 
Genetic Klotho deficiency in rodents mimics the features of chronic renal failure with 
accelerated atherosclerosis, osteopenia, soft tissue calcifications, pulmonary emphysema, and 
altered glucose metabolism.
19
 Klotho, expressed in the kidney, parathyroid glands and the 
choroid plexus
19
 is a single transmembrane protein whose extracellular domain is cleaved by 
the α-secretases ADAM 10 and 17112 to generate large amounts of soluble α-Klotho into 
blood, urine, and cerebrospinal fluid.
104, 113
 Klotho activates ion channels TRPV5 and 6 in the 
nephron and the intestine
105, 114
 and regulates the sodium-phosphate co-transporter type-2a 
(NaPiIIa) independently of fibroblast growth factor 23 (FGF23).
104
  
Klotho acts as an essential co-factor for FGF23, a phosphaturic hormone produced by 
osteocytes: it forms a ternary complex with the fibroblast growth factor receptor 1c 
(FGFR1c), therewith increasing its affinity for FGF23.
115
 Thus, FGF23 and Klotho synergize 
to regulate phosphate homeostasis
116
 by promoting renal phosphate excretion: they do so via 
reduction of the number of NaPiIIa and NaPiIIc phosphate co-transporters in the proximal 
tubule and reduction of intestinal phosphate absorption, the latter following a decreased 
synthesis of 1,25-dihydroxy vitamin D3 (1,25D).
102
 
Rodent studies indicate that soluble α-Klotho levels in urine and blood are highly 
correlated with renal Klotho expression. Studies in patients with chronic kidney disease 
(CKD) or acute kidney injury indicate a decrease of Klotho expression with decreasing 
GFR;
117
 however, these studies encompass a limited number of patients and Klotho levels 
were only measured semi-quantitatively by western blots performed in concentrated urine 
samples. 
It has been shown that the curvilinear slope of FGF23 versus estimated glomerular 
filtration rate (eGFR) ascends earlier than that of parathyroid hormone (PTH) as renal 
function declines.
17, 118
 However, whether the fall in serum Klotho precedes or follows the 
rise in FGF23 in patients with CKD remains a matter of debate because a reliable assay for 
soluble Klotho has not been available until recently, and data on the expression, function, and 
regulatory mechanisms of soluble α-Klotho are scarce.119  
Our cross-sectional study is the first systematic determination of serum levels of Klotho, 
FGF23, PTH, 1,25D and other parameters of mineral metabolism performed in a cohort of 
patients with chronic renal insufficiency at CKD stages 1 to 5D. We were looking for the 
sequence of the changes in the mentioned parameters over the entire range of CKD stages; the 
question is relevant as Klotho or FGF23 may turn out to be the most sensitive markers of 
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early kidney disease, of its progression as well as of its prognosis, besides the fact that both 
might become future therapeutic targets.
22
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Methods 
Study participants and procedures 
Eighty-seven patients at different stages of chronic kidney disease (stages 1 to 5D) 
without polycystic kidney disease or previous kidney transplantation, aged 18-84 years were 
enrolled in the study. Twenty healthy volunteers, aged 17-40 years without history of renal 
disease served as control group.  
Sitting blood pressure was measured by a nurse, a blood sample was drawn and a spot 
urine sample (2
nd
 fasting morning urine, after voiding the 1
st
 urine of the day prior to the visit 
to the clinics) was collected between 8 a.m. and 10 a.m.. The serum and urine aliquots were 
stored at -80°C. Blood was analyzed for Klotho, FGF23, PTH, phosphate, ionized calcium, 
creatinine, 25-hydroxyvitamin D (25D) and 1,25D. Spot urine was analyzed for phosphate 
and creatinine.  
The study was conducted according to the Declaration of Helsinki and the guidelines of 
Good Clinical Practice (GCP) and was approved by the local Ethics Committee. Patients and 
healthy volunteers gave written, informed consent. 
 
Analytical methods 
Soluble alpha Klotho has been measured in serum, a novel ELISA method detecting 
human soluble α-Klotho has been developed first by establishing a monoclonal antibody with 
strong affinity for human α-Klotho protein, recognizing with high selectivity the tertiary 
protein structure of its extracellular domain. The established protein detection method has 
been subsequently tested comparing the serum α-Klotho levels of human healthy volunteers 
with a human case where the α-Klotho gene carries a mutation that hinders the expression of 
α-Klotho in the test subject. The results of the analysis indicated that the ELISA system can 
specifically detect and measure the circulating serum α-Klotho levels in humans.119 The intra-
assay coefficient of variation was 3.1% (Immuno-Biological Laboratories Co., Ltd. Japan). 
The levels of carboxy-terminal FGF23 (2
nd
 generation, Immutopics Inc., San Clemente 
CA, USA) and intact PTH (Biomerica Inc., Newport Beach CA, USA) were measured in 
serum by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s 
protocol.  
Serum 25D has been determined using the RIA-kit from Diasorin (Stillwater, MN, 
USA), and serum 1,25D by radioimmunoassay (immunodiagnostic systems, Fountain Hills, 
AZ, USA). Phosphate concentrations were measured in serum and urine using standard 
methods. Creatinine in serum and urine was assayed by the IDMS traceable modified Jaffé 
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method. The glomerular filtration rate was estimated by using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation. The tubular maximum phosphate 
reabsorption per glomerular filtration rate (TmP/GFR) in mmol/l of glomerular filtrate (GF) 
was calculated according to the formula of Brodehl.
120
  
 
Statistical Analysis 
LOWESS (locally weighted scatter plot smoothing) function of Klotho, 1,25D, FGF23 
and PTH versus eGFR in patients with CKD were fitted by the default function of the STATA 
version 11.2 software (STAT Corp., College Station, TX) with a bandwidth of 0.8. Based on 
the LOWESS shape, a linear model was fitted for Klotho and 1,25D and the crude mean 
change for each 1 ml/min/1.73 m
2
 estimated eGFR. By fitting an a priori model containing 
the binomial covariates vitamin D supplementation, 1,25D treatment, calcium administration 
(calcium acetate, calcium supplement), calcium-free phosphate binder (sevelamer, 
lanthanum), the respective mean estimated changes of Klotho and 1,25D were adjusted for 
these concomitant medications that potentially influence the rate change. The association 
between FGF23 and PTH with eGFR was not linear and thus we fitted a segmented model 
consisting of smoothly fitted plateau and quadratic function to estimate the departure point of 
the curve from the plateau.  
Differences among the CKD stages and healthy volunteers were compared
 
by one-way 
analysis of variance. When the difference was significant, statistical
 
comparisons were 
performed by using Dunnett’s post hoc test with the health volunteers as a reference group. 
Univariate Pearson’s correlation was used to test for associations between continuous 
variables. All P values were two-sided for the comparison between the groups and values 
below 0.05 were considered as statistically significant. Statistical analyses were performed 
using SAS statistical software version 9.2. (SAS Institute Inc., Cary, NC). 
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Results 
Patients were studied at the outpatient clinic of the Division of Nephrology at the 
University Hospital of Zurich, Switzerland from March 2010 to May 2011. Table 1 shows the 
characteristics of 87 CKD patients (mean age 53 years, 52% male) and 20 healthy volunteers 
serving as controls (mean age 33 years, 60% male). The patients were classified into CKD 
stages according to the CKD EPI equation:
121
 19% of the participants belonged to CKD stage 
1, 22% to stage 2, 13% to stage 3, 23% to stage 4 and 23% to stage 5 (18 (21%) 5D, median 
dialysis vintage 1.4 years). Causes of nephropathies in CKD patients were: hypertensive 
nephropathy (n=21, 10% biopsy confirmed), IgA-nephropathy (n=12, 83% biopsy 
confirmed), diabetic nephropathy (n=6, 33% biopsy confirmed), focal segmental 
glomerulosclerosis (n=10, 100% biopsy confirmed), Lupus nephritis (n=5, 80% biopsy 
confirmed), glomerulonephritis (n=13, 46% biopsy confirmed), other kidney diseases (n=16, 
81% biopsy-proven), and CKD of unknown etiology (n=5). The frequency of 1,25D and 
phosphate binder treatment increased with advancing CKD stages. At any CKD stage, 
approximately half of the patients were supplemented with nutritional vitamin D (Table 1). 
None of the patients were currently or had been treated in the past with bisphosphonates. 
Healthy volunteers received no medication. 
 
Relationship between serum levels of Klotho, 1,25D, FGF23 and PTH with eGFR 
Klotho,  1,25D, FGF23 and PTH levels were plotted versus eGFR and the respective 
relationships analyzed by the LOWESS function, a statistical technique without assumption 
on the shape of the relationship.  
Figure 1a reveals that serum Klotho and eGFR were associated linearly. Klotho levels 
continuously declined with progressive degree of severity of renal insufficiency; this fitted a 
linear model (r
2
=0.41, P<0.0001) and it was estimated that the crude mean Klotho level 
declines by 6.1 pg/ml (95CI 4.7 to 7.5 pg/ml, P<0.0001) as GFR declines by 1 ml/min. We 
estimated that the mean Klotho change was -5.7 pg/ml (95%CI -4.1 to -7.5 pg/ml, P<0.0001) 
for each -1 ml/min GFR change adjusted for concomitant medications that possible affect the 
relationship (r
2
=0.42, P<0.0001). In the post hoc analysis adjusted for multiple testing by 
using volunteers as a reference group, Klotho levels were already significantly lower than 
normal in patients with CKD stage 2 (mean difference -380.6 pg/ml, 95%CI -621.4 to -139.7 
pg/ml; P<0.05) and approximately decreased by half from CKD 1 to CKD 5 (mean difference 
-504.1 pg/ml (95%CI -747.4 to -260.8; P<0.05).  
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Figure 1b confirms that 1,25D and eGFR are linearly associated and 1,25D levels 
decline with progressive GFR loss justifying the fitting of a linear model. We estimated that 
the crude mean 1,25D levels decrease by 0.32 ng/l (95%CI 0.22 to 0.41 ng/l, P<0.0001) as 
eGFR declines by 1 ml/min. The adjustment for the concomitant medications did only 
marginally change the estimated 1,25D slope: 0.36 ng/l (0.25 to 0.48; P<0.0001). The post 
hoc analysis revealed that patients at CKD stage 3 to 5 had lower 1,25D levels compared to 
volunteers.  
It is noteworthy that, FGF23 and PTH both showed a plateau at approximately CKD 
stages 1 to 3  for PTH and 1 to 2 for FGF23 and an exponential increase at higher respective 
CKD stages in the LOWESS function (Figures 1c and 1d),whereas Klotho and 1,25D levels 
were linearly associated with eGFR (Figures 1a and 1b). This fitted a segmented, nonlinear 
model that consists of two segments connected in a smooth fashion, and we estimated the 
departure point of the curve from the plateau. The iterative optimization converges after 7 
(Klotho vs. eGFR) and 13 iterations (1,25D vs. eGFR), respectively. We estimated that the 
FGF23 curve departs from the plateau (63.9 RU/ml) at a GFR of 48.6 ml/min (95%CI 41.0 to 
56.1 ml/min) whereas the PTH curve departs from the plateau (53.2 ng/ml), at a eGFR of 35.3 
ml/min (95%CI 21.7 to 50.0 ml/min). The post hoc analysis further confirmed that FGF23 
increases earlier in the course of renal insufficiency, compared to PTH: Serum levels of 
FGF23 in patients at CKD stages 4 and 5 were different from those obtained in healthy 
volunteers whereas for PTH the serum levels were only different from healthy volunteers at 
CKD stage 5. 
 
Phosphate, calcium and 25-hydroxy vitamin D 
Mean serum phosphate levels increased only modestly in patients at higher CKD stages: 
0.96 mmol/l ± 0.17 mmol/l in CKD 1 to 1.69 mmol/l ± 0.48 mmol/l in CKD5 (Table 2). 
Hyperphosphatemia (> 1.1 mmol/l) was present in 46% of the participating subjects, mostly 
in patients with CKD stages 4 and 5, as expected. The LOWESS function of serum phosphate 
versus eGFR indicated a plateau at early CKD stages and an exponential increase at advanced 
CKD stages (Figure 2a). The departure point of the curve from the plateau was at an eGFR of 
35.1 ml/min (95%CI 21.7 to 49.0 ml/min) estimated by fitting a segmented non linear 
regression model. The post hoc analysis showed that only patients at CKD stage 5 had serum 
phosphate levels different from those observed in healthy volunteers, similar to what was seen 
for PTH. The maximal tubular phosphate reabsorption rate (TmP/GFR) remained normal and 
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unchanged for patients at CKD stage 1 to 3 and then declined at stage 4 (mean difference -
0.16 mmol/l, 95%CI -0.31 to -0.01, post hoc analysis) (Table 2). 
The ionized calcium levels remained unchanged across CKD stages 1 to 5 and the 
LOWESS function remained within the interquartile range (1.19 mmol/l -1.21 mmol/l) of the 
healthy volunteers (Figure 2b). The serum levels of 25-hydroxy vitamin D (25D) also 
remained unchanged across CKD stages 1 – 5 (Figure 2C). 
57 of 106 
Discussion 
The present report is the first illustration of the sequential changes of the serum levels of the 6 
key actors which govern mineral metabolism in renal insufficiency, i.e. Klotho, 1,25D, 
FGF23, PTH, phosphate and calcium: as depicted in Figure 3, serum levels of soluble alpha-
Klotho and 1,25D decrease in parallel with the progressive decline in glomerular filtration 
rate, and both do so before a rise in serum levels of FGF23 (at 49 ml/min GFR) followed by a 
rise in serum levels of PTH (at 35 ml/min GFR) can be detected. Ultimately, i.e. at CKD stage 
4 and onwards, serum levels of phosphate start rising, whereas serum levels of ionized 
calcium remained unchanged across all CKD stages included in this cross-sectional study. 
With respect to the chronological sequence FGF23-PTH, these results are in agreement with 
those recently published by Isakova et al
17
 who pointed to the fact that the rise in serum 
FGF23 does precede the rise in serum PTH in the course of development of renal 
insufficiency. As to the rise in FGF23 itself in a state of Klotho deficiency, it is thought to be 
the consequence of phosphorous accumulation as recently demonstrated by preclinical studies 
which showed absence of said rise in klotho-/- mice fed a low phosphate diet.
22
 
The present study illustrates the fact that serum levels of both 1,25D and Klotho decline 
“hand in hand” with progression of renal insufficiency. Given the current limitations of the 
respective techniques, it remains speculative to declare at that current stage of knowledge 
which of both levels declines first, i.e. what is the cause and what is the consequence: on one 
hand, Tsujikama et al have suggested that Klotho might have an enzymatic ability to modify a 
receptor or ligand autonomously influencing the activity of 1-alpha hydroxylase; on the other 
hand, the same authors demonstrated that 1,25D itself modulates the expression of Klotho.
109
 
Therefore further studies, in particular prospective studies remain to be carrying out to clarify 
this point. 
In summary, we postulate that an initial renal tubular damage leads to down-regulation of 
expression of both Klotho and 1-alpha-hydroxylase, and that the ensuing cascade comprising 
the rise in FGF23 and in PTH is the consequence: Indeed, insufficient production of Klotho 
known to occur at the level of both the parathyroid gland and the distal tubule in condition of 
renal insufficiency
19, 104
 leads to peripheral resistance to FGF23 at both anatomical sites, and 
FGF23 thus can no longer suppress PTH secretion nor maintain phosphate homeostasis, as 
already suggested by Kuro-o.
118
 
Conclusion 
These data elevate the newly assayable serum level of soluble alpha-Klotho to the rank of 
potentially most sensitive biomarker for early detection of kidney damage; in patients with 
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various nephropathies it triggers new hopes for effective monitoring of the impact of future 
therapeutic interventions. 
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Figure 1 Scatter plot graphs of A) Klotho, B) 1,25-dihydroxy-vitamin D3 (1,25D), C) 
carboxy-terminal fibroblast growth factor 23 (FGF23) and D) intact parathyroid hormone 
(PTH) versus estimated glomerular filtration rate (eGFR) in chronic kidney disease patients 
with locally weighted scatter plot smoothing (LOWESS). Each symbol represents one patient.  
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Figure 2 Scatter plot graphs of A) serum phosphate, B) ionized calcium and C) 25-hydroxy-
vitamin D (25D), versus estimated glomerular filtration rate (eGFR) in chronic kidney disease 
patients with locally weighted scatter plot smoothing (LOWESS). Each symbol represents one 
patient.  
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Figure 3 Overlaid LOWESS lines for Klotho, 1,25-dihydroxy-vitamin D3 (1,25D), carboxy-
terminal fibroblast growth factor 23 (FGF23) and intact parathyroid hormone (PTH) versus 
estimated glomerular filtration rate (eGFR) in chronic kidney disease patients with locally 
weighted scatter plot smoothing (LOWESS). 
 
 
 
 
 
 
 
 
 
 
Table 1 Characteristics of healthy volunteers (HV) and of patients with chronic kidney disease (CKD). 
 
 
HV 
N=20 
CKD 1 
N=17 
CKD 2 
N=19 
CKD 3 
N =11 
CKD 4 
N=20 
CKD 5 
N=20 
Age – years 32 ± 5 41 ± 14 40 ± 12 57 ± 15 64 ± 12 61 ± 17 
Sex – no. (%)       
     Female 8 (40.0) 7 (41.2) 12 (63.2) 6 (54.6) 9 (45.0) 8 (40.0) 
     Male 12 (60.0) 10 (58.8) 7 (36.8) 5 (45.4) 11 (55.0) 12 (60.0) 
Body mass index - kg per m
2
 23 ± 2 28 ± 6 23 ± 5 28 ± 4 28 ± 6 24 ± 6 
Creatinine – mg/dl 0.9 ± 0.1 0.8 ± 0.2 1.0 ± 0.2 1.5 ± 0.3 2.5 ± 0.7 6.6 ± 2.8 
eGFR - ml/min per 1.73m
2
  99.1 ± 11.6 104.1 ± 11.3 81.1 ± 16.5 42.6 ± 6.0 25.3 ± 5.8 5.7 ± 4.9 
Blood pressure – mmHg       
     Systolic 124 ± 9 139 ± 13 130 ± 13 144 ± 21 145 ± 19 138 ± 26 
     Diastolic 126 ± 7 83 ± 10 84 ± 8 78 ± 14 79 ± 12 69 ± 21 
Medication - no. (%)       
      25-hydroxy-vitamin supplement  7 (41.0) 7 (36.8) 9 (81.8) 13 (65.0) 8 (40.0) 
     1,25-dihydroxy vitamin D3 treatment  0 (0.0) 1 (5.3) 1 (9.1) 5 (25.0) 4 (20.0) 
     Calcium-free phosphate binder  0 (0.0) 0 (0.0) 0 (0.0) 2 (10.0) 9 (45.0) 
     Calcium administration  4 (23.6) 5 (26.3) 1 (9.1) 5 (25.0) 10 (50.0) 
     Bicarbonate supplement  0 (0.0) 0 (0.0) 0 (0.0) 4 (20.0) 1 (5.0) 
     Diuretics  1 (5.9) 2 (10.5) 4 (36.4) 14 (70.0) 6 (30.0) 
     Prednisone  3 (17.7) 6 (31.6) 4 (36.4) 2 (10.0) 3 (15.0) 
Abbreviations: eGFR – estimated glomerular filtration rate. Values are means ± standard deviation and numbers (percentage) 
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Table 2 Parameters of phosphate metabolism in healthy volunteers (HV) and in patients with chronic kidney disease (CKD) 
 
Parameter HV 
N=20 
CKD 1 
N=17 
CKD 2 
N=19 
CKD 3 
N =11 
CKD 4 
N=20 
CKD 5 
N=20 
Serum       
     Klotho - pg/ml 
 Q1/Median/Q3 
1200.8 ± 385.0 
862.9/1153.1/1371.9 
964.3 ± 398.8 
703.2/880.1/1159.8 
1049.7 ± 1037.5 
623.1/749.1/952.6 
638.1 ± 128.7 
423.9/622.6/684.9 
539.7 ± 165.1 
415.1/490.2/640.8 
460.2 ± 222.8 
282.2/368.3/612.9 
     FGF23 - RU/ml 
 Q1/Median/Q3 
27.5 ± 22.0 
4.2/27.1/39.2 
89.9 ± 54.3 
51.1/95.5/101.4 
65.1 ± 41.7 
38.2/50.8/82.9 
137.7 ± 45.9 
50.8/140.1/161.3 
377.2 ± 370.3 
141.6/307.0/434.0 
1200.6 ± 416.4 
910.0/1356.7/1586.4 
     PTH - ng/ml 
 Q1/Median/Q3 
43.3 ± 15.7 
27.2/44.8/58.3 
43.0 ± 17.0 
32.7/42.3/52.8 
40.4 ± 16.6 
31.2/39.6/45.9 
87.4 ± 63.8 
25.9/76.6/88.1 
129.1 ± 71.2 
87.2/119.4/156.7 
422.8 ± 392.7 
196.9/314.2/492.4 
     25-hydroxy-vitamin D - μg/l 
 Q1/Median/Q3 
25.4 ± 12.0 
19.6/22.3/29.2 
15.1 ± 8.9 
8.5/15.4/20.8 
20.4 ± 8.2 
14.7/20.9/24.0 
17.6 ± 6.0 
7.9/19.3/19.8 
21.9 ± 12.5 
12.7/18.8/27.3 
25.9 ± 12.4 
16.7/26.2/34.1 
     1,25-dihydroxy-vitamin D3 - ng/l 
 Q1/Median/Q3 
51.2 ± 10.0 
45.0/49.6/57.2 
48.5 ± 25.9 
34.3/41.6/55.4 
45.7 ± 19.6 
29.8/48.0/51.7 
31.7 ± 12.7 
13.0/35.4/42.3 
27.12 ± 8.7 
19.3/30.4/33.0 
21.8 ± 15.0 
13.2/13.8/26.5 
     Phosphate - mmol/l 
 Q1/Median/Q3 
1.01 ± 0.12 
0.92/0.98/1.10 
0.96 ± 0.17 
0.84/0.96/1.08 
1.02 ± 0.24 
0.85/1.02/1.24 
1.01 ± 0.22 
0.62/1.03/1.11 
1.15 ± 0.21 
1.04/1.09/1.30 
1.69 ± 0.48 
1.33/1.58/1.99 
     Ionized Calcium - mmol/l 
 Q1/Median/Q3 
1.20 ± 0.02 
1.19/1.20/1.21 
1.20 ± 0.05 
1.18/1.20/1.21 
1.24 ± 0.09 
1.20/1.22/1.25 
1.23 ± 0.05 
1.18/1.22/1.24 
1.22 ± 0.06 
1.17/1.21/1.25 
1.19 ± 0.08 
1.14/1.17/1.22 
Spot Urine       
     Phosphate - mmol/l 
 Q1/Median/Q3 
22.9 ± 13.6 
13.9/21.3/30.0 
12.8 ± 5.8 
8.1/13.1/16.1 
16.5 ± 12.9 
4.1/15.3/21.2 
9.7 ± 4.6 
5.4/8.7/11.2 
12.5 ± 5.4 
9.4/11.3/15.9 
- 
     TmP/GFR - mmol/l/GFR 
 Q1/Median/Q3 
0.88 ± 0.12 
0.79/0.86/0.99 
0.85 ± 0.16 
0.74/0.81/0.97 
0.89 ± 0.23 
0.69/0.85/1.13 
0.86 ± 0.25 
0.42/0.91/1.03 
0.72 ± 0.16 
0.60/0.78/0.85 
- 
Abbreviations: Q1 - 0.25 quartile; Q3 - 0.75 quartile, 1,25-dihydroxy-vitamin D3 (1,25D), FGF23 - carboxy-terminal fibroblast growth factor 23, 
PTH - intact parathyroid hormone, TmP/GFR - Tubular maximum phosphate reabsorption per ml of glomerular filtrate. 
9 Conclusion 
The optimal control of mineral ion metabolism and hormonal factors, as PTH secretion and 
Vitamin D regulation, are crucial for the therapy and treatment of chronic kidney disease 
patients. In the past years a global initiative has tried to provide guidelines regarding renal 
disease patients considering a variety of different demographics. This global initiative has 
been founded as the National Kidney Foundation Disease Outcomes Quality Initiative (NKF 
KDOQI) and has ever since provided evidence-based clinical practice guidelines for all stages 
of chronic kidney disease (CKD) and related complications since 1997. Acknowledged as a 
foundation to update based on clinical trial outcome and knowledge generated via scientific 
efforts, these guidelines have been improving the diagnosis and treatment of kidney disease 
throughout the world. The KDOQI Guidelines have changed the practices of numerous 
specialties and disciplines and improved the lives of thousands of kidney patients.
122
 
Nevertheless the renal community has come to an agreement that current data obtained via 
clinical trials lack to provide hard fact based evidence. Most of the trial data available are post 
hoc observational data collected from various registries over the years.
123
 The field of renal 
disease research is lacking well designed prospective interventional trials to provide the 
answers needed regarding questions to influence treatment outcome and therapy choices, per 
example what the optimal levels are for PTH, Ca and Pi to avoid either adynamic bone 
disease or vascular calcification. It is very limiting to use observational trial data to draw 
causality and effect. The field of renal disease research has come to an agreement that basic 
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science findings have gained the respect to be further investigated in a clinical setting, 
opening the field to a couple of new screening parameters, as an example phosphate 
homeostasis. These factors have been mainly identified as phosphaturic hormones FGF23 and 
103
available for a longer period of time, hence most of the research has been conducted in 
house and data collected has been only shared on closed communities. Since early 2000 
commercially available antibodies against these specific hormones have provided a valid 
possibility to measure these parameters, qualifying and quantifying them for a clinical setting. 
Although they have not reached complete validation as screening parameters in daily clinical 
practice; their importance based on basic science data has been fully acknowledged. FGF23 
has been the most important factor to draw the essential line called bone kidney axis, leading 
to confirmation that renal insufficiency has the consequence of negatively impacting multiple 
organs very early in disease. Furthermore the importance of FGF23 has gained a wide field of 
impact, associating it with higher levels of mortality, vascular calcification, and mineral bone 
disease, just to name a few. The knowledge gained, associating FGF23 with specific 
pathophysiological phenotypes has been broadened over the past 10 years, however, we have 
not yet established what the exact levels of harm are versus how much FGF23 is actually 
needed to maintain and control phosphate in the system. Since specifically in the past two 
years we have learned a great deal regarding the specific pathways and activation of FGF23 
receptor and the way they regulate in order to avoid excessive levels of phosphate and vitamin 
D and their resulting toxic effects.
124
 This knowledge has to be taken further investigating the 
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levels of FGF23 in specific clinical patient cohorts. Research efforts focusing on using FGF23 
as a therapy target will provide further clarification.  
In the early nineties, the discovery of Klotho has impacted the view on the renal 
pathophysiology in an essential way. What started as a discovery of an anti aging molecule 
has shortly after been associated with renal insufficiency. Since the Klotho knockout mice 
present a highly similar phenotype as chronic kidney disease patients. The detection of Klotho 
in various tissues has provided insight in a wide range of functionalities of Klotho as a 
paracrine Proteohormone. The definition as a Proteohormone, is based on the fact that Klotho 
as a single transmembrane domain protein, with a c-terminal extracellular domain that when 
cleaved acts as a paracrine hormone. The Klotho knockout phenotype in mice shows a high 
similarity to the FGF23 knockout phenotype which has led to the association that additional to 
its anti aging features; Klotho has the ability to act as a co factor to FGF23. The cleaved c-
terminal domain of Klotho, which acted as a paracrine hormone showed to have the tubular 
epithelial cell as a target. The tubular epithelia cells are at the same time the location where 
FGF23 receptor activation occurs, leading to the signaling pathway initialized via proper 
binging to the receptor. Early in the discovery of the 23
rd
 member of the FGF family it has 
been established that FGF23 needs for accurate binding a heparin/sulfate cofactor; solely it 
can only peripherally bind to the receptor, initializing only weak and improper activation. As 
Klotho has been determined to be expressed in different tissues, it has been of great interest to 
evaluate its function and signaling pathway as a circulating hormone (soluble α-Klotho). 
Klotho has the molecular features to form with FGF23 a tertiary complex that as a construct 
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has the conformational ability to bind with high affinity to the FGFR1c receptor and initialize 
proper signaling. The signaling pathways impact on the phosphate transporters in the 
proximal tubules, including renal phosphate wasting, due to suppression of phosphate 
reabsorption. Specifically the action on the Na/Pi co-transporters has been studied in relation 
to the FGF23/Klotho complex. The results obtained have identified that Klotho is essential for 
FGF23 to fulfill its endocrine biological activity. On the other hand, Klotho has the ability to 
act as an individual factor with no co-dependence on another molecule or hormone. 
Specifically its ability to retain calcium when overexpressed via activation of the TRPV5b 
channel and its influence on the activation of Vitamin D. Overall FGF23 and Klotho have 
been recognized as potential factor to elucidate the pathophysiology in early chronic kidney 
disease.  
There are in general a smaller number of patients with CKD stages 1-2, than stages 3 – 5, 
mostly because the symptoms of renal failure are established over a longer period of time in 
silence. This small number has the implication that evidence based research is lacking hard 
facts to fully establish the picture how exactly renal failure starts in dependence of hormonal 
and mineral ion factors.  
Kuro et al. have hypothesized that Klotho has the potential to be the earliest biomarker to 
implicate potential chronic renal failure, since it has been shown that it is the first factor to 
become imbalanced when renal disease starts. 
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This hypothesis plays an important role since the stages of CKD 1 – 2 have not been 
elucidated enough due to late capturing of the disease progress in daily clinical practice. It is 
yet to be clarified what the implication would be regarding certain levels of Klotho in relation 
to disease outcome, forecasting 10 years. 
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10 Outlook 
This doctoral thesis focused exclusively on the expression and implications of phosphaturic 
hormones and parameters involved in phosphate homeostasis in a human setting. The findings 
and conclusions of this doctoral thesis are solely based on a clinical research effort.  
For future purposes to elucidate the role and regulation of both phosphaturic hormones, 
Klotho and FGF23, in the development and outcomes of CKD and ADPKD, and in order to 
establish them in a potential therapeutic setting, it is of essence to further study their 
molecular mechanisms and regulatory pathways in a basic research setting. 
Focusing on ADPKD there are currently two well established rodent models that can be used 
to further study FGF23 expression patters and regulatory functions; the HanSPRD rat and the 
PKD mouse model. Since we already established that FGF23 expression levels reach a 
significantly high level in our ADPKD cohort independently of their age or glomerular 
filtration rate, research on the HanSPRD rat could clarify the origin of expression of FGF23 in 
ADPKD. Current opinion reached an agreement that FGF23 is sequestered by the osteocytes, 
yet it would be of great interest when in the setting of PKD the bone reacts with increasing the 
expression levels and under which circumstances this can be manipulated. Observation should 
involve as well implication to bone mineral density and bone development and later turn over 
regarding FGF23 expression. One could study the implications of FGF23 while suppressing 
FGF23 on genetic levels via knock out or blunting the FGF23 function with an FGF23 
neutralizing antibody. Since we could agree that FGF23 activity could not be studied solely, 
yet in relation to Klotho acting as his co-factor for increasing receptor affinity and leading to 
full activation of the receptor. It is of essence to study Klotho expression both in tissue as well 
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as soluble α-Klotho levels acting as an endocrine hormone. Since our findings pointed to the 
possible hypothesis that the FGF23 resistance established in our ADPKD patients might be 
due to the lack of Klotho circulating in serum.  
It is important that these studies would need to be conducted in both models: the HanSPRD 
rat model, and the PKD mouse. Simply due to the fact that the cyst development in the PKD 
mouse model resembles more closely the cyst development in a human setting, meaning that 
the cyst development is initiated on the level of the distal convoluted tubule, whereas cyst 
development in the HanSPRD rat originates primarily from the proximal tubules. We 
postulated in regards to our findings, that the lower levels of Klotho in our Human ADPKD 
patients might be secondary to the patients’ cyst development and the destruction of the 
endothelial cell architecture on the levels of the distal convoluted tubule; bearing in mind that 
the transmembrane Klotho expression is located on the level of the distal convoluted tubule.  
Early in the course of scientific research on the phosphaturic hormones the question came up 
if FGF23 is a friend or a foe? And Klotho gained great respect to be implied with anti-aging. 
As both act as either paracrine or endocrine hormones it is a fact that they are influencers and 
complete suppression of both leads to pathophysiological states as described earlier. In the 
case of ADPKD and its specific manifestations in regards to high levels of FGF23 and lower 
levels of Klotho in early stages of the disease it would be very interesting to study on one 
hand the exposure of high levels of FGF23 long term and the implication on the bone. One 
could postulate that under constant FGF23 accumulation the bone lowers the production. This 
down regulation might go along with the bone starting to lower its turnover. On the other 
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hand, suppressing of Klotho completely in ADPKD might lead to complete resistance of 
FGF23 and accumulation of phosphate leading to possible vascular calcification and 
hypertension. More possibly since Klotho suppression was associated with calcium 
accumulation in serum. Overall long term exposure to either excessive exposure of complete 
suppression in regards to both FGF23 and Klotho would provide further clarification 
regarding calcium/phosphate homeostasis and kidney bone axis. 
We have implied that further knowledge regarding the role and regulation of these 
phosphaturic hormones might as well lead to contribution to novel therapeutic approaches and 
here it needs to be stated that Klotho as a individual player and co-factor to FGF23 might be 
the more promising therapeutic tool, meaning to be supplemented to avoid FGF23 
accumulation and maintain the phosphate homeostatic function in association with FGF23. To 
conclude, before a therapeutic approach might be considered, the position of FGF23 and 
Klotho as sensitive markers regarding maintenance of mineral homoeostasis in various 
chronic kidney disease states needs to be further established. 
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